SG Americas Securities
APRE icon

SG Americas Securities’s Aprea Therapeutics APRE Stock Holding History

SG Americas Securities’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-29,920
Closed -$2.92M – 3817
2021
Q2 		$2.92M Sell
29,920
-2,874
-9% -$266K 0.01% 893
2021
Q1 		$3.35M Buy
32,794
+31,633
+2,725% +$3.69M 0.02% 722
2020
Q4 		$114K Sell
1,161
-372
-24% -$177K ﹤0.01% 2964
2020
Q3 		$738K Buy
+1,533
New +$858K ﹤0.01% 1386

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SG Americas Securities's APRE Position: Q3 2021 in Review

SG Americas Securities sold out of Aprea Therapeutics (APRE) in Q3 2021, closing a stake of 29,920 shares — an estimated $2.92M sold.

SG Americas Securities first reported a position in APRE in Q3 2020 and held it in 4 quarters. The position peaked at $3.35M in Q1 2021. 39 funds tracked by Wall St. Rank hold APRE as of Q3 2021.

  • SG Americas Securities reported no remaining Aprea Therapeutics position as of Q3 2021 after selling out during the quarter.
  • SG Americas Securities sold 29,920 Aprea Therapeutics shares in Q3 2021, an estimated $2.92M.
  • SG Americas Securities first reported a position in Aprea Therapeutics in Q3 2020 and held it in 4 quarters.
  • SG Americas Securities's Aprea Therapeutics position peaked at $3.35M in Q1 2021.
  • 39 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2021.

Based on SG Americas Securities's 13F filing for Q3 2021, filed 1 Nov 2021.